VRCA Key Statistics, Chart & Performance
The current stock price of VRCA is 8.33 USD. In the past month the price increased by 62.7%. In the past year, price increased by 21.73%.
VRCA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.98 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20.02 | 500.60B | ||
| MRK | MERCK & CO. INC. | 12.08 | 264.21B | ||
| PFE | PFIZER INC | 7.82 | 142.31B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.34 | 111.38B | ||
| ZTS | ZOETIS INC | 19.79 | 55.30B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.55 | 22.66B | ||
| VTRS | VIATRIS INC | 5.25 | 14.10B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.31 | 11.12B | ||
| CORT | CORCEPT THERAPEUTICS INC | 94.99 | 8.79B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.74B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About VRCA
Company Profile
Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 71 full-time employees. The company went IPO on 2018-06-15. The firm's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. The company is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Company Info
VERRICA PHARMACEUTICALS INC
44 West Gay Street, Suite 400
West Chester PENNSYLVANIA 19380 US
CEO: Ted White
Employees: 71
Phone: 14844533300
VERRICA PHARMACEUTICALS INC / VRCA FAQ
What does VERRICA PHARMACEUTICALS INC do?
Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 71 full-time employees. The company went IPO on 2018-06-15. The firm's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. The company is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
What is the current price of VRCA stock?
The current stock price of VRCA is 8.33 USD. The price increased by 1.46% in the last trading session.
What is the dividend status of VERRICA PHARMACEUTICALS INC?
VRCA does not pay a dividend.
What is the ChartMill rating of VERRICA PHARMACEUTICALS INC stock?
VRCA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of VRCA stock?
VERRICA PHARMACEUTICALS INC (VRCA) operates in the Health Care sector and the Pharmaceuticals industry.
Would investing in VERRICA PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VRCA.
Can you provide the ownership details for VRCA stock?
You can find the ownership structure of VERRICA PHARMACEUTICALS INC (VRCA) on the Ownership tab.
VRCA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to VRCA. When comparing the yearly performance of all stocks, VRCA is one of the better performing stocks in the market, outperforming 94.59% of all stocks.
VRCA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VRCA. VRCA has a bad profitability rating. Also its financial health evaluation is rather negative.
VRCA Financial Highlights
Over the last trailing twelve months VRCA reported a non-GAAP Earnings per Share(EPS) of -3.41. The EPS increased by 81.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.61% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VRCA Forecast & Estimates
For the next year, analysts expect an EPS growth of 91.12% and a revenue growth 325.61% for VRCA